Top Page
Medicenna Therapeutics Corp
(TSX:MDNA)
Medicenna Therapeutics Corp (MDNA) vs. S&P 500 (SPY)
Medicenna Therapeutics Corp Business Overview & Revenue Model
Medicenna Therapeutics Corp Financial Statement Overview
| Breakdown | ||||
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| -5.00K | -5.00K | -38.00K | -40.00K | ― | EBIT |
| -19.66M | -21.64M | -22.30M | -17.19M | -8.21M | EBITDA |
| -18.67M | -16.30M | -22.54M | -17.25M | -8.27M | Net Income Common Stockholders |
| -25.47M | 1.55M | -22.65M | -17.18M | -8.31M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 16.98M | 33.60M | 20.54M | 40.38M | 37.70M | Total Assets |
| 19.13M | 36.45M | 23.46M | 42.25M | 38.00M | Total Debt |
| 0.00 | 0.00 | 0.00 | 34.00K | 67.31K | Net Debt |
| -16.98M | -33.60M | -20.54M | -30.34M | -22.63M | Total Liabilities |
| 13.94M | 6.96M | 2.62M | 4.11M | 1.85M | Stockholders Equity |
| 5.19M | 29.49M | 20.84M | 38.15M | 36.15M |
| Cash Flow | Free Cash Flow | |||
| -16.26M | -12.66M | -23.58M | -15.31M | -8.95M | Operating Cash Flow |
| -16.26M | -12.66M | -23.58M | -15.31M | -8.95M | Investing Cash Flow |
| 0.00 | -13.05M | 10.05M | 5.01M | -15.00M | Financing Cash Flow |
| 0.00 | 24.76M | 3.88M | 18.26M | 44.28M |
Medicenna Therapeutics Corp Technical Analysis
Medicenna Therapeutics Corp Peers Comparison
Medicenna Therapeutics Corp Corporate Events
Medicenna Therapeutics Corp has presented promising preclinical data for MDNA113, a novel tumor-targeted and conditionally activated anti-PD-1-IL-2 bifunctional Superkine, at the 2025 AACR Meeting. MDNA113 is designed to target IL-13Rα2, which is overexpressed in several ‘immunologically cold’ tumors, providing a potentially superior approach compared to existing therapies. The data highlights MDNA113’s ability to enhance tumor targeting and conditional activation, offering a differentiated alternative in the competitive landscape of anti-PD-1-IL-2 therapies, potentially benefiting millions of cancer patients worldwide.
Spark’s Take on TSE:MDNA Stock
According to Spark, TipRanks’ AI Analyst, TSE:MDNA is a Neutral.
Medicenna’s overall score reflects significant financial challenges, with ongoing losses and cash flow issues. However, the company’s low debt levels and promising clinical trial results for MDNA11 provide potential upside. Technical analysis indicates a neutral sentiment, and the valuation underscores the speculative nature of the stock.
To see Spark’s full report on TSE:MDNA stock, click here.
Medicenna Therapeutics Corp has presented promising results from its ABILITY-1 clinical trial at the 2025 AACR Annual Meeting, showcasing the effectiveness of MDNA11 both as a monotherapy and in combination with KEYTRUDA. The trial revealed significant objective response rates in patients with advanced cancers, particularly those resistant to immune checkpoint inhibitors. The data supports the potential of MDNA11 to transform treatment paradigms for difficult-to-treat tumors, with ongoing enrollment in the Phase 2 combination dose expansion arm. The safety profile of MDNA11 remains acceptable, with most adverse events being mild and transient. These findings reinforce MDNA11’s potential as a potent and safe immunotherapy option.
Spark’s Take on TSE:MDNA Stock
According to Spark, TipRanks’ AI Analyst, TSE:MDNA is a Neutral.
Medicenna Therapeutics Corp.’s stock score reflects the company’s financial challenges and negative cash flows. However, positive trial results and strategic initiatives offer potential for future growth. The technical indicators suggest neutral sentiment, while the valuation highlights the speculative nature of the investment. These factors combine to give a modest overall score, emphasizing both the risks and opportunities present for investors.
To see Spark’s full report on TSE:MDNA stock, click here.
Medicenna Therapeutics Corp announced that its President and CEO, Dr. Fahar Merchant, will present at the 2025 Bloom Burton & Co. Healthcare Investor Conference in Toronto. This event provides an opportunity for Medicenna to engage with U.S., Canadian, and international investors, potentially enhancing its market visibility and investor relations. The conference serves as a platform for the company to update stakeholders on its progress and strategic direction in the healthcare sector.
Spark’s Take on TSE:MDNA Stock
According to Spark, TipRanks’ AI Analyst, TSE:MDNA is a Neutral.
Medicenna Therapeutics Corp.’s stock score reflects the company’s financial challenges and negative cash flows. However, positive trial results and strategic initiatives offer potential for future growth. The technical indicators suggest neutral sentiment, while the valuation highlights the speculative nature of the investment. These factors combine to give a modest overall score, emphasizing both the risks and opportunities present for investors.
To see Spark’s full report on TSE:MDNA stock, click here.
Medicenna Therapeutics Corp announced that its President and CEO, Dr. Fahar Merchant, will present at the Jones Healthcare and Technology Innovation Conference in Las Vegas. This participation highlights Medicenna’s active engagement with investors and industry stakeholders, potentially enhancing its visibility and strategic positioning in the immunotherapy sector.
Medicenna Therapeutics Corp announced that it will present updates from its Phase 1/2 ABILITY-1 Study of MDNA11 and pre-clinical data for MDNA113 at the upcoming American Association for Cancer Research Annual Meeting 2025. These presentations highlight Medicenna’s progress in developing innovative cancer therapies, potentially enhancing its position in the immunotherapy market and offering new treatment options for patients with advanced solid tumors.
Medicenna Therapeutics Corp has announced promising results from its ABILITY-1 study, showcasing the potential of its MDNA11 therapy in combination with Merck’s KEYTRUDA® for treating advanced solid tumors. The study revealed that MDNA11 significantly expands stem-like CD8+ T cells, leading to a 30% objective response rate in checkpoint-resistant patients and a 78% disease control rate when combined with KEYTRUDA®. These findings suggest that MDNA11 could enhance the efficacy of immune checkpoint inhibitors and improve outcomes for patients with difficult-to-treat cancers.
Medicenna Therapeutics Corp announced its financial results for the third quarter of fiscal 2025, highlighting significant progress in its ABILITY-1 trial, which combines MDNA11 with KEYTRUDA. The trial demonstrated a 78% disease control rate with promising responses, including complete and partial responses in patients with treatment-refractory tumors. The company also reported strong financial backing, ensuring operations are funded through mid-2026, and shared its excitement about upcoming milestones that could further validate its clinical development program.
Medicenna Therapeutics Corp announced its participation in two key investor conferences in February 2025, where it seeks to engage with investors through presentations and one-on-one meetings. This strategic move aims to elevate the company’s visibility and strengthen its position in the biotechnology sector by showcasing their innovative immunotherapy developments.